Journal of Science Research International (JSRI). *ISSN: 2456 – 6365*

REVIEW ARTICLE

APPLICATIONS OF CRISPR-CAS9 IN HUMAN DISEASES: A REVIEW OF LATEST RESEARCH ADVANCES

Nitesh Singh*, Anupam Unnikrishnan,
Trisha Divakaran and Athira Vijaysankaran
Department of Biotechnology,
Pillai College of Arts, Commerce and Science (Autonomous)., Panvel, Navi Mumbai
*Corresponding author E-mail: niteshsingh@mes.ac.in

DOI: https://doi.org/10.5281/zenodo.17446042

Abstract:

Clustered Regularly Interspaced Short Palindromic Repeats associated with Cas9 (CRISPR-Cas9). technology has revolutionized the field of molecular biology and genetics, offering unprecedented precision and efficiency in genome editing. CRISPR-associated RNA-guided endonuclease Cas9 is an effective gene editing tool with widespread applications in medicine, agriculture, and fundamental studies of gene functions. Using an RNA-guided Cas9 system, DNA sequences can be easily edited, modified, imaged, and annotated in virtually any organism of choice. The relative simplicity, versatility and robustness of CRISPR-Cas9 has provided an advantage that sets it apart from other gene-editing tools. This review article summarizes the latest advancements in the applications of CRISPR-Cas9 for the treatment of human diseases.

Keywords: CRISPR Cas9, Gene Therapy, Genetic Disorders, Mutations.

Introduction:

Gene editing, a revolutionary field in biotechnology, empowers scientists to precisely modify the DNA within an organism's genome (Chen, 2019). This capability holds immense potential for a wide range of applications, from treating genetic diseases to enhancing agricultural crops. One of the most groundbreaking tools in gene editing is the CRISPR-Cas9 system, which has rapidly emerged as a game-changer due to its simplicity, efficiency, and versatility (Gaj *et al.,* 2016). To understand the significance of CRISPR-Cas9, it's crucial to delve into the history of genome editing and the evolution of this transformative technology. The history of genome editing dates back several decades and has witnessed a progression of techniques that have enabled scientists to manipulate DNA with increasing precision. Early methods involved laborious and limited approaches, such as random mutagenesis and homologous recombination, which had significant limitations in terms of efficiency and specificity (Gaj *et al.,* 2016). These techniques were useful but lacked the precision needed for targeted and controlled modifications of specific genes. The dawn of the 21st century brought about zinc-finger nucleases (ZFNs). and transcription activator-like effector nucleases (TALENs)., which marked a significant leap forward in genome editing (Chen, 2019). These protein-based systems provided higher specificity compared to earlier methods, but they were still complex and required custom engineering for each new target, making them time-consuming and costly to develop. The breakthrough that revolutionized genome editing came with the discovery of the CRISPR-Cas9 system. Derived from the bacterial immune system, CRISPR-Cas9 offered a remarkably efficient and versatile tool for precise DNA manipulation (Ran *et al.,* 2013). CRISPR-Cas9 stands for "Clustered Regularly Interspaced Short Palindromic Repeats" and "CRISPR-associated protein 9." In this method, the Cas9 protein functions as a molecular scissor to cut the DNA at the targeted site while a guide RNA molecule targets specific DNA sequences. This break in the DNA triggers the cell's repair mechanisms, allowing researchers to introduce targeted modifications or insert new genetic material. What sets CRISPR-Cas9 apart is its adaptability and ease of use. Unlike previous methods, which required custom-designed proteins for each target, CRISPR-Cas9 can be easily reprogrammed by altering the guide RNA sequence, enabling researchers to target virtually any gene of interest (Gaj *et al.,* 2016). This breakthrough democratized genome editing, making it accessible to a broader range of scientists and accelerating research across various fields, from medicine to agriculture. The applications of CRISPR-Cas9 are far-reaching and transformative. In medicine, it holds the potential to correct genetic mutations responsible for inherited diseases, offering hope for previously untreatable conditions. Researchers are also exploring its use in creating disease models for a better understanding of pathogenesis and in developing more efficient drug screening platforms. In agriculture, CRISPR-Cas9 is being employed to enhance crop yields, increase nutritional value, and improve resistance to pests and environmental stressors. The technology's ability to precisely edit plant genomes offers a sustainable approach to address food security challenges. Furthermore, CRISPR-Cas9 has implications in ecological conservation, by potentially aiding in the preservation of endangered species, and in biotechnology, by enabling the production of biofuels and other valuable compounds.

Genome Editing Before CRISPR Cas9

Before the development of the CRISPR-Cas9 gene editing technology, there were other methods and techniques that were used for gene editing, though they were generally less efficient and precise. A few notable methods that were used before CRISPR-Cas9 are:

1. **Zinc Finger Nucleases (ZFNs)**: ZFNs were one of the first engineered nucleases used for targeted gene editing. They were created by fusing zinc finger proteins, which can bind to specific DNA sequences, with a nuclease domain that cuts the DNA. The idea was to design these proteins to target a specific gene sequence and induce a double-strand break, which would then be repaired by the cell's DNA repair machinery, potentially introducing desired changes in the process. ZFNs paved the way for more precise gene editing methods (Chen, 2019).
2. **Transcription Activator-Like Effector Nucleases (TALENs)**: TALENs are another type of engineered nuclease that was developed for gene editing. Similar to ZFNs, TALENs are designed to bind to specific DNA sequences and induce double-strand breaks. They utilize transcription activator-like effectors (TALEs)., which are derived from bacteria, to recognize

specific DNA sequences. TALENs offered increased specificity compared to earlier methods but still required significant design and customization (Chen, 2019).

3. **Homologous Recombination**: This is a naturally occurring process in cells that repairs double-strand breaks in DNA using a template strand. Researchers used this process to edit genes by introducing a DNA template with the desired changes into cells along with factors that induce double-strand breaks. However, homologous recombination is less efficient and requires cells to be in specific phases of the cell cycle for optimal editing (Hoshijima *et al.,* 2016).
4. **Microinjection and Viral Vectors**: These methods involve physically introducing foreign genetic material into cells. In microinjection, a small glass needle is used to inject DNA or RNA directly into the cell's nucleus. Viral vectors, such as retroviruses and adenoviruses, can also be used to deliver genetic material into cells. These methods were often used for research purposes and gene therapy, but they lack the precision of modern gene editing techniques (Schierberl *et al.,* 2013).

All these methods had limitations in terms of efficiency, specificity, and ease of use. CRISPR-Cas9 revolutionized the field of gene editing by providing a highly efficient and relatively easy way to target specific DNA sequences and induce precise modifications. Its widespread adoption has led to significant advancements in various fields, from basic biological research to potential therapeutic applications (Hsu *et al.,* 2014).

History of CRISPR Cas9

The CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats). system was first identified in the late 1980s and early 1990s as an unusual sequence pattern in the genomes of bacteria and archaea (Chen, 2019). Researchers noted the repetitive nature of these sequences interspersed with unique sequences. In the early 2000s, researchers speculated that these CRISPR sequences might have a role in the immune system of bacteria, potentially providing protection against viral infections. This theory gained traction as more studies were conducted. By around 2007, research started to demonstrate that CRISPR sequences are involved in a bacterial defence mechanism against invading viruses. CRISPR was found to be a part of the prokaryotic immune system, where bacteria could store snippets of viral DNA from previous infections and use them to identify and destroy the virus upon re-infection (Chen, 2019). In 2011, a study conducted showed that Cas9 acts as molecular scissors that can be programmed to target specific DNA sequences guided by RNA molecules. This discovery laid the groundwork for the revolutionary gene-editing technology. In 2012, researchers repurposed the CRISPR-Cas9 system for precise gene editing in a wide range of organisms, including human cells. The ability to easily target and modify specific genes within an organism's genome was a significant leap forward in genetic engineering. The CRISPR-Cas9 technology quickly gained traction due to its simplicity and efficiency. By 2013, multiple research groups demonstrated its effectiveness in editing genes in various organisms, from bacteria and plants to animals. This opened up countless possibilities in fields like medicine, agriculture, and basic research (Gaj *et al.,* 2016). The rapid advancement of CRISPR-Cas9 brought forth important ethical and regulatory discussions about its use in editing the human germ-line (eggs, sperm, embryos). The potential to make heritable changes to the human genome raised concerns about unintended consequences and the need for responsible use. In subsequent years, researchers developed variations of the CRISPR-Cas9 system to enhance its precision, reduce off-target effects, and expand its capabilities. This led to the development of technologies like base editing and prime editing, which offer even more precise control over genetic modifications. CRISPR-Cas9 has revolutionized genetic research and has the potential to transform fields like medicine, agriculture, and biotechnology. However, its use also raises important ethical considerations, and ongoing research and discussions continue to shape its responsible application.

Components of CRISPR Cas9

CRISPR-Cas9 is a revolutionary gene-editing technology that enables scientists to modify DNA sequences within an organism's genome with remarkable precision. It consists of :-

1. **Guide RNA (gRNA):** The guide RNA is a molecule that carries the sequence information to target a specific region of the DNA. It consists of two parts: the CRISPR RNA (crRNA). that contains the sequence complementary to the target DNA, and the trans-activating CRISPR RNA (tracrRNA). that helps in the processing of the crRNA (Chen, 2019).
2. **CRISPR Array:** The CRISPR array is a DNA sequence in the genome that contains repeated sequences (repeats). interspersed with unique spacer sequences. These spacer sequences are derived from viral or other foreign DNA that the organism has encountered. The CRISPR array serves as a memory bank of past infections.
3. **Cas9 Protein:** Cas9 (CRISPR-associated protein 9). is an enzyme that acts as molecular scissors. It can cut the DNA strands at the target location specified by the guide RNA. Cas9 is guided by the gRNA to the precise location on the DNA where the editing is intended to occur.
4. **Protospacer Adjacent Motif (PAM):** PAM is a short DNA sequence that is recognized by the Cas9 enzyme. It is required for the Cas9 protein to bind to the target DNA and initiate the editing process. The PAM sequence is specific to the organism and varies among species (Chen, 2019).
5. **Single Guide RNA (sgRNA):** In some cases, the separate crRNA and tracrRNA molecules are combined into a single synthetic guide RNA (sgRNA)., simplifying the delivery process and ensuring accurate targeting (Chen, 2019).

Mechanism of CRISPR Cas9

Cas9 encourages a DSB at a particular genomic location, which aids in genome editing. The target locus normally experiences one of two fundamental changes when Cas9 cleaves it. DNA damage repair pathways: the error-prone NHEJ or the high-fidelity HDR route or, alternatively, attain the editing result that is intended (Wei *et al.,* 2020). The NHEJ procedure is used to re-ligate DSBs in the absence of a repair template, leaving mutations known as insertion/deletion (indel). scars. NHEJ. NHEJ can be used to mediate gene knockouts due to the occurrence of indels. Premature stop codons and frameshift mutations inside a coding exon are possible outcomes. Additionally, several DSBs can be exploited that could facilitate greater genome deletions. A different important pathway for DNA repair is HDR. HDR can be used to produce precise, specified alterations at a target locus in the presence of an exogenously delivered repair template, even though it normally occurs at lower and significantly more variable frequencies than NHEJ (Wei *et al.,* 2020). Using the repair template either take the shape of customary double-stranded DNA targeted structures around the insertion with homology arms single-stranded DNA oligonucleotides (ssODNs)., or sequence. The latter offers a feasible and simple way for producing minor modifications to the genome, including the integration of single-nucleotide mutations to look for genetic abnormalities that cause disease. In contrast to NHEJ, HDR often only becomes active in dividing cells, and depending on the cell type and state, the genetic locus, and other factors, its effectiveness can vary significantly (Ran *et al.,* 2013).

Applications of CRISPR Cas9 in Human Disease Therapy

With the rapid development in CRISPR-Cas 9 system, it has been widely applied in gene therapy for treating various human diseases. The applications of CRISPR Cas9 to treat some of the genetic disorders are summarized as follows:

1) HIV/AIDS

The HIV provirus residing in cells that make up the viral reservoir is not targeted by current antiretroviral drugs, even though they can effectively stop HIV replication and prevent transmission (Das *et al.,* 2019). The success of the treatment is based on two effects: additive or even synergistic virus inhibition and an increase in the genetic threshold for development of drug resistance. (Zhao N, *et al.,* 2017). Due to the drug, viral rebound from this reservoir will be caused by therapy interruption. Treatment for HIV infection is lifelong. Therefore, new treatment approaches are being researched with the intention that the proviral DNA is permanently inactivated, potentially resulting in a cure. (Das *et al.,* 2019). Proposed genetic assaults on proviral HIV range from antisense RNA to RNA aptamers to RNA decoys, as well as transgenes that express transdominant negative viral proteins. Two intriguing strategies employ CRISPR Cas9 and RNA inference (RNAi). processes to launch a sequence-specific attack on the viral genome (Zhao *et al.,* 2017). The CRISPR–Cas9 system can be used to modify host cells in such a way that they are no longer vulnerable to HIV infection. CRISPR–Cas9 can target cellular factors involved in HIV replication, but this may have negative consequences on cell physiology. Instead of targeting host cofactors, viral DNA can be directly targeted in HIV-infected cells by introducing the Cas9 protein and anti-viral gRNA. Cells, on the other hand, can be utilized in conjunction with CRISPR reagents to directly target and cleave the reverse transcribed viral DNA produced during infection. (Das *et al.,* 2019). CRISPR-Cas9 is a recent tool that was developed to cleave DNA genomes in a sequence-specific manner. The complete machinery of CRISPR-Cas9 systems require the transgene-mediated expression consisting of the Cas9 endonuclease and the guide RNA (gRNA). that mediates the sequence specificity. The potential for virus suppression by the cleavage of the integrated HIV DNA genome has been described in many research teams. Researches proposed a novel viral escape mechanism that is facilitated by the cellular DNA repair machinery, more specifically the nucleotide insertions, deletions (indels)., or substitutions introduced at the cleavage site by the nonhomologous end joining (NHEJ). mechanism. Only when genome regions that can absorb such modifications without the loss of viral replication capacity are assaulted, cleavage-induced NHEJ repair cause exceptionally fast viral escape. Although the antiviral impact of two anti-HIV gRNAs was enhanced, most combinations still resulted in viral escape (through NHEJ-introduced mutations).

Intriguingly, it was identified that two double-gRNA combinations durably suppressed virus replication.These combinations efficiently sterilized the contaminated culture and prevented viral escape. Examining the HIV genomes that were still present found inactivating indels at both sites, stopping viral replication. Additionally, it has been suggested that two CRISPR-Cas9 attacks on HIV DNA could result in genome excision (Zhao *et al.,* 2017).

2) Transfusion Dependent Beta-Thalassaemia (TDT) and Sickle Cell Disease (SCD)

Beta-Thalassaemia and sickle cell disease are both caused by the mutations in specific genes that lead to abnormal haemoglobin production, resulting in severe health issues (Frangoul *et al.,* 2021). In case of beta thalessaemia, (Badat *et al.,* 2023) mutations in the HBB gene lead to reduced or absent production of beta- globin chains. TDT results in reduced or absent beta globin synthesis (Frangoul *et al.,* 2021). In sickle cell disease, a mutation in the HBB gene results in the production of abnormal haemoglobin (HbS) causing red blood cells to become mishappen and leading to various health complications (Demirci *et al.,* 2019). Both TDT and SCD can be cured by allogenic bone marrow transplantation, but this therapy is applicable to all the patients. Genome-wide association studies have found that single nucleotide polymorphisms (SNPs) are associated with high expression of fetal haemoglobin in adults. Some of these SNPs, which are found in the BCL11A locus on chromosome 2, are connected to TDT and SCD that are less severe. BCL11A is a zinc finger-containing transcription factor that inhibits the expression of gamma-globin and fetal haemoglobin in erythroid cells. The SNPs linked to fetal haemoglobin are located in an enhancer specific to erythroid cells, which inhibits the expression of BCL11A and promotes the expression of fetal haemoglobin. The CRISPR-Cas9 nuclease system, a bacterial immune system that can cleave DNA from bacteriophages or plasmids, allows for the programmed targeting of insertions or deletions (indels) at a particular genomic DNA locus. CRISPR-Cas9 gene-editing methods were used in hematopoietic stem and progenitor cells (HSPCs) to reduce BCL11A expression in erythroid-lineage cells, restore gamma-globin synthesis, and reactivate production of fetal haemoglobin in an effort to mimic the phenotype of hereditary persistence of fetal haemoglobin (Frangoul *et al.,* 2021).

3) Crohn’s Disease and Rheumatoid Arthritis

The PTPN2 gene, also known as Protein Tyrosine Phosphatase Non-Receptor Type 2, is a gene that encodes a protein involved in regulating various cellular processes, including immune responses and inflammation. Variations in the PTPN2 gene have been associated with several autoimmune diseases, including Crohn's disease. Crohn's disease resulting from combination of genetic and environmental factors is a chronic inflammatory bowel disease that can affect any part of the digestive tract. Specific variations (single nucleotide polymorphisms or SNPs) within the PTPN2 genePTPN2 (rs478582-C) resulting in amino acid change from thymine to cytosine have been found to be associated with an increased risk of Crohn's disease. These variations may affect the function of the PTPN2 protein and consequently impact immune responses and inflammatory processes in the gut. The PTPN2 gene is thought to play a role in regulating the activity of immune cells and maintaining the balance between pro-inflammatory and anti-inflammatory signalling pathways. Variations in this gene could potentially disrupt this balance, contributing to the development of chronic inflammation seen in Crohn's disease (Shaw *et al.,* 2021).

The PTPN22 gene (protein tyrosine phosphatase non-receptor type 22) has been extensively studied in the context of autoimmune diseases, including Rheumatoid Arthritis (RA). This gene encodes a protein called lymphoid tyrosine phosphatase (Lyp), which is involved in regulating the immune system. Several studies have indicated a strong association between certain variants of the PTPN22 gene and an increased risk of developing Rheumatoid Arthritis. The most well-known variant is called rs2476601, which results in base change from a guanine to an adenosine resulting in the arginine amino acid residue at position 620 to be changed to a tryptophan. This variant is associated with an increased risk of developing RA and other autoimmune disorders. The PTPN22 gene plays a role in regulating immune cell signalling, including T cells and B cells. Variants of this gene, particularly the rs2476601 variant, have been linked to altered immune responses and increased autoimmunity. The exact mechanisms by which these variants contribute to RA are still being studied, but it's believed that they may lead to unregulated immune responses and increased inflammation. In both cases, the potential role of CRISPR-Cas9 involves precise genome editing to correct genetic mutations, regulate gene expression, or modulate immune responses. However, it's important to note that using CRISPR-Cas9 for therapeutic purposes involves significant challenges, including ensuring the accuracy and safety of gene editing, delivery of the CRISPR components to the target cells, and potential off-target effects. Clinical trials and further research are essential to validate the effectiveness and safety of these approaches in treating Crohn's disease, rheumatoid arthritis, and other complex diseases (Shaw *et al.,* 2021).

4) Rett Syndrome (RTT).

Rett Syndrome (RTT) is an X-linked genetic disorder affecting brain. This is a rare disease with incidence of approximately 1 in 10,000 females. The main cause of the disease is mutation in MECP2(*methyl-CpG-binding protein 2*) gene. MECP2 gene is responsible for producing a protein MeCP2 which is crucial for brain development. This disease is characterized by 2 copies of MECP2 gene on single X-chromosome (Le *et al.,* 2019). Patients with RTT do not generally show symptoms around 6-18 months and then develop neuropsychiatric abnormalities like problems with language and communication, motor abnormalities, memory loss and autistic features. Abnormalities in sleep/wake pattern with nap during daytime and night-time laughter are characteristic features of RTT (Tsuchiya *et al.,* 2015). The human MECP2 locus can be accurately modified using a CRISPR Cas9 technology. The restoration of the MECP2 gene's physiological expression level is crucial for the reversion of disease symptoms. Thus, the correction of mutations in the endogenous MECP2 gene shows potential for RTT syndrome gene therapy. CRISPR Cas9-mediated mutation repair restores endogenous expression of the MECP2 gene, potentially resolving RTT symptoms completely (Le *et al.,* 2019).

5) Cancer

i) Bladder Cancer

CRISPR/Cas9 systems have salient features that make them desirable for building logic circuits. The sgRNA must associate with the Cas9 protein to form an effector complex that directs double-stranded DNA breaks. Therefore, CRISPR/Cas9 systems can be integrated into AND logic gates. This system also has drawbacks. To keep sgRNAs in the cell nucleus, sgRNA gene products are often transcribed from Pol III promoters such as U3 and U6 (Smargon *et al.,* 2022). In contrast to Pol II promoters, Pol III promoters are generally constitutive and lack species/tissue specificity. One way to solve this problem is to create RNA molecules with ribozyme sequences at both ends of the sgRNA. The ribozyme- sgRNA-ribozyme primary transcript undergoes autocatalytic cleavage, releasing the sgRNA precisely into the cell nucleus. A novel two-step cascaded modular AND gate based on the CRISPR-cas9 system can be used to target human bladder cancer using the hTERT and hUP II promoters as two input devices. The hTERT promoter is believed to be cancer-specific

It is a promoter in various cancers and is also activated in the germ-line. The hUPII promoter is a bladder-specific promoter that can drive gene expression only in urothelial cells. A circuit constructed by combining promoters had the ability to selectively identify bladder cancer cells expressing both telomerase and uroplakin, which could be detected using a luciferase reporter gene. A modified circuit (SC-1) successfully induced bladder cancer-specific gene expression, showing strong luciferase expression in bladder cancer cells, but little luciferase expression in other cell types. Not detected. In cells with hTERT promoter activity, this circuit induces much higher luciferase expression than her single transfection of the hTERT-Rluc construct. The engineered circuit effectively amplifies the input promoter response to bladder cancer cells and generates an endogenous signal that can be a useful detection tool in vitro. Here the selection of bladder cancer cells is required. Another important feature of circuit design is modularity. Such circuits may also control the behaviour of bladder cancer cells. By regulating corresponding genes, this circuit potently and specifically inhibits bladder urothelial carcinoma cell proliferation, induces apoptosis, and reduces cell motility (Liu *et al.,* 2014).

ii) Childhood High Grade Glioma (HGG)

High-Grade Gliomas are aggressive brain tumours that primarily affect the central nervous system and are more common in children than in adults. Mutation found in histone 3 (H3) is a key factor in paediatric HGG. The H3 mutations that take place on the histone tail results in alterations in gene expression and methylation pattern. DNA methylation patterns are increasingly being used to classify and subtype all types of paediatric brain tumours, and prognostic methylation biomarkers have also been proposed. The established primary cancer stem cell (CSC) lines produced from paediatric HGG with and without the H3 K27 mutation enable functional research on the cells involved in tumourigenesis, tumour relapse, and treatment failure. CRISPR enables unprecedented ease of genomic modification. Novel genes required for CSC growth can be found by doing CRISPR knockout screens with an epigenetic/chromatin modifier library on two CSC lines obtained from H3 K27-mutated paediatric HGG. This knockout resulted in the discovery that the genes UBE2N, CHD4, LSM11, EED, KANSL1 and KANSL3 are required for CSC proliferation and may be therapeutic candidates in paediatric HGG. Thus, CRISPR Cas9 mediated knock-out can be used to study the role of these genes for treatment targets in HGG (Wenger *et al.,* 2023).

6) Alzhiemer's Disease

Alzheimer's Disease (AD) is a progressive neurodegenerative disorder, characterized by deposition of amyloid-beta peptide (Aβ)., as well as hyperphosphorylated tau aggregation resulting in formation of plaques. Aβ is a 38–43 amino acid peptide produced from amyloid precursor protein (APP) by two different proteases, β-secretase and γ-secretase. Aβ accumulation plays a central role in AD pathogenesis involved in familial AD(FAD). It has been found that pathogenic mutations in the App gene or presenilin 1 gene(PS1), encoding a catalytic subunit of γ-secretase, can cause FAD through increased Aβ production and/or a change in the ratio of aggregation-prone Aβ species (Nagata *et al.,* 2018). An autosomal dominant variant of early-onset AD is caused by the M146L mutation in the PS1 gene (PSEN1), which encourages a relative rise in the production of the more aggregation-prone Aβ42. Not just the brain but even the peripheral cells of mutation carriers show this alteration. In human fibroblasts, the PSEN1 M146L allele may be specifically disrupted using the Streptococcus pyogenes CRISPR-Cas9 system. A disruption of mutant alleles by CRISPR-Cas9 results in reduced extracellular Aβ42/40 ratios. CRISPR-Cas9 treatment also affects the overall PS1 conformation and reduces PS1 levels. Thus, CRISPR Cas9 proves to be effective in selectively targeting the PSEN1 M146L allele and counteracting the AD-associated phenotype (Konstantinidis *et al.,* 2022).

Challenges:

While CRISPR-Cas9 technology holds great promise for human disease treatment, there are several challenges that need to be addressed for its successful application. Some of these challenges include:

1. **Off-Target Effects:** One of the main concerns with CRISPR-Cas9 is its potential to cause unintended genetic modifications at sites other than the intended target. Off-target effects can lead to unpredictable and potentially harmful consequences, such as causing new genetic mutations or disrupting important genes. Researchers are actively working to improve the specificity of CRISPR-Cas9 to minimize off-target effects.
2. **Delivery Methods:** Getting the CRISPR-Cas9 components (guide RNA and Cas9 protein) into the target cells and tissues is a significant challenge. The delivery method needs to be efficient and specific to ensure that the gene-editing machinery reaches the desired cells without causing damage or triggering an immune response.
3. **Immune Response:** The introduction of foreign components, such as Cas9 proteins, into the body can trigger an immune response. This response could reduce the effectiveness of the treatment and potentially lead to adverse effects. Developing strategies to mitigate immune responses to CRISPR-Cas9 is essential for its clinical success.
4. **Ethical and Regulatory Concerns:** The use of CRISPR-Cas9 for gene editing in humans raises complex ethical considerations. The potential for unintended consequences and heritable changes in the germline cells has led to discussions about the responsible use of this technology. Regulatory frameworks need to be established to ensure proper oversight and accountability.

5. **Delivery to Specific Tissues:** Different diseases may require precise targeting of specific tissues or cell types. Achieving accurate and efficient delivery to these target cells can be challenging, especially in cases where the affected cells are deep within the body or are not easily accessible.
6. **Long-Term Effects and Safety:** Long-term consequences of genetic modifications introduced by CRISPR-Cas9 are not yet fully understood. It's essential to assess the safety and stability of edited genes over extended periods of time to ensure that unintended effects do not arise later in life.
7. **Limited Editable Genetic Material:** Not all genetic diseases can be addressed using CRISPR-Cas9 due to the nature of the genetic mutations involved. Some mutations may be too complex or located in regions that are difficult to access and edit using the current technology.
8. **Multigenic Diseases:** Many diseases are influenced by multiple genes, making it challenging to achieve therapeutic effects through editing a single gene. Addressing multi-genic diseases requires more advanced approaches, such as targeting multiple genes simultaneously or modifying regulatory networks.
9. **Cancer Risk:** In the process of repairing DNA, the cell's DNA repair machinery might introduce additional mutations, potentially increasing the risk of cancer. Ensuring that the gene-editing process doesn't inadvertently promote cancer development is crucial.
10. **Limited Clinical Evidence:** While CRISPR-Cas9 has shown success in preclinical studies and some early-stage clinical trials, more rigorous and comprehensive clinical evidence is needed to determine its long-term safety and efficacy for various diseases.

Overcoming these challenges will require ongoing research, collaboration between scientists, clinicians, ethicists, and regulators, as well as careful consideration of the potential benefits and risks of using CRISPR-Cas9 for human disease treatment.

Conclusion:

CRISPR-Cas9 technology holds significant promise for revolutionizing human disease treatment. Its precision and efficiency in editing the genetic code offer potential solutions for a wide range of genetic disorders and diseases. By enabling scientists to edit or modify specific genes with unprecedented accuracy, CRISPR-Cas9 has opened up new avenues for developing targeted therapies and personalized medicine approaches.

While there has been remarkable progress in using CRISPR-Cas9 for human disease treatment, several challenges remain. Off-target effects, ethical concerns surrounding germ-line editing, and the potential for unintended consequences still need to be carefully addressed. Regulatory frameworks must be established to ensure the responsible and safe use of this technology.

CRISPR-Cas9 has demonstrated the ability to correct genetic mutations in various disease conditions. However, further research and long-term studies are necessary to fully understand the safety, efficacy, and potential long-term effects of using CRISPR-Cas9 in human patients.

In the coming years, advancements in CRISPR-Cas9 technology, along with continued collaboration between scientists, ethicists, clinicians, and policymakers, will determine its role in shaping the future of human disease treatment. While challenges persist, the ongoing developments in this field offer hope for improved therapeutic options and potentially transformative changes in the way we approach and treat genetic diseases.

References:

1. Ran, F., Hsu, P., Wright, J., et al. (2013). Genome engineering using the CRISPR-Cas9 system. *Nature Protocols, 8*, 2281–2308. https://doi.org/10.1038/nprot.2013.143
2. Nagata, K., Takahashi, M., Matsuba, Y., et al. (2018). Generation of App knock-in mice reveals deletion mutations protective against Alzheimer's disease-like pathology. *Nature Communications, 9*, 1800. https://doi.org/10.1038/s41467-018-04238-0
3. Badat, M., Ejaz, A., Hua, P., et al. (2023). Direct correction of haemoglobin E β-thalassaemia using base editors. *Nature Communications, 14*, 2238. https://doi.org/10.1038/s41467-023-37604-8
4. Das, Binda C. S., & Berkhout, B. (2019). Elimination of infectious HIV DNA by CRISPR-Cas9. *Current Opinion in Virology, 38*, 81–88. https://doi.org/10.1016/j.coviro.2019.07.001
5. Shaw, A. M., Qasem, A., & Naser, S. A. (2021). Modulation of PTPN2/22 function by spermidine in CRISPR-Cas9-edited T-cells associated with Crohn's disease and rheumatoid arthritis. *International Journal of Molecular Sciences, 22*(16), 8883. https://doi.org/10.3390/ijms22168883
6. Hsu, P. D., Lander, E. S., & Zhang, F. (2014). Development and applications of CRISPR-Cas9 for genome engineering. *Cell, 157*(6), 1262–1278. https://doi.org/10.1016/j.cell.2014.05.010
7. Chen, Y.-C. (2019). *Introductory chapter: Gene editing technologies and applications*. IntechOpen. https://doi.org/10.5772/intechopen.85499
8. Gaj, T., Sirk, S. J., Shui, S. L., & Liu, J. (2016). Genome-editing technologies: Principles and applications. *Cold Spring Harbor Perspectives in Biology, 8*(12), a023754. https://doi.org/10.1101/cshperspect.a023754
9. Zhao, Wang G., & Das, Berkhout B. (2017). Combinatorial CRISPR-Cas9 and RNA interference attack on HIV-1 DNA and RNA can lead to cross-resistance. *Antimicrobial Agents and Chemotherapy, 61*(12), e01486-17. https://doi.org/10.1128/AAC.01486-17
10. Liu, Y., Zeng, Y., Liu, L., et al. (2014). Synthesizing AND gate genetic circuits based on CRISPR-Cas9 for identification of bladder cancer cells. *Nature Communications, 5*, 5393. https://doi.org/10.1038/ncomms6393
11. Frangoul, A., Altshuler, D., Cappellini, M. D., Chen, Y. S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., Ho, T. W., Kattamis, A., Kernytsky, A., Lekstrom-Himes, J., Li, A. M., Locatelli, F., Mapara, M. Y., de Montalembert, M., Rondelli, D., Sharma, A., ... Corbacioglu, S. (2021). CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. *The New England Journal of Medicine, 384*(3), 252–260. https://doi.org/10.1056/NEJMoa2031054
12. Tsuchiya, Y., Minami, Y., Umemura, Y., Watanabe, H., Ono, D., Nakamura, W., Takahashi, T., Honma, S., Kondoh, G., Matsuishi, T., & Yagita, K. (2015). Disruption of MeCP2 attenuates

circadian rhythm in CRISPR/Cas9-based Rett syndrome model mouse. *Genes to Cells, 20*(12), 992–1005. https://doi.org/10.1111/gtc.12305

13. Wenger Karlsson, I., Kling, T., et al. (2023). CRISPR-Cas9 knockout screen identifies novel treatment targets in childhood high-grade glioma. *Clinical Epigenetics, 15*, 80. https://doi.org/10.1186/s13148-023-01498-6
14. Wei, T., Cheng, Q., Min, Y. L., Olson, E. N., & Siegwart, D. J. (2020). Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue-specific genome editing. *Nature Communications, 11*, 3232. https://doi.org/10.1038/s41467-020-17029-3
15. Demirci, L., Leonard, A., Haro-Mora, J. J., Uchida, N., & Tisdale, J. F. (2019). CRISPR/Cas9 for sickle cell disease: Applications, future possibilities, and challenges. *Advances in Experimental Medicine and Biology, 1144*, 37–52. https://doi.org/10.1007/5584_2018_331
16. Hoshijima, K., Jurynec, M. J., & Grunwald, D. J. (2016). Precise genome editing by homologous recombination. *Methods in Cell Biology, 135*, 121–147. https://doi.org/10.1016/bs.mcb.2016.04.008
17. Schierberl, K. C., & Rajadhyaksha, A. M. (2013). Stereotaxic microinjection of viral vectors expressing Cre recombinase to study the role of target genes in cocaine conditioned place preference. *Journal of Visualized Experiments, 77*, 50600. https://doi.org/10.3791/50600
18. Le, T. T. H., Tran, N. T., Dao, T. M. L., Nguyen, D. D., Do, H. D., Ha, T. L., Kühn, R., Nguyen, T. L., Rajewsky, K., & Chu, V. T. (2019). Efficient and precise CRISPR/Cas9-mediated MECP2 modifications in human-induced pluripotent stem cells. *Frontiers in Genetics, 10*, 625. https://doi.org/10.3389/fgene.2019.00625
19. Smargon, M., Madrigal, A. A., Yee, B. A., Dong, K. D., Mueller, J. R., & Yeo, G. W. (2022). Crosstalk between CRISPR-Cas9 and the human transcriptome. *Nature Communications, 13*(1), 1125. https://doi.org/10.1038/s41467-022-28719-5
20. Konstantinidis, E., Molisak, A., Perrin, F., Streubel-Gallasch, L., Fayad, S., Kim, D. Y., Petri, K., Aryee, M. J., Aguilar, X., György, B., Giedraitis, V., Joung, J. K., Pattanayak, V., Essand, M., Erlandsson, A., Berezovska, O., & Ingelsson, M. (2022). CRISPR-Cas9 treatment partially restores amyloid-β 42/40 in human fibroblasts with the Alzheimer's disease PSEN1 M146L mutation. *Molecular Therapy – Nucleic Acids, 28*, 450–461. https://doi.org/10.1016/j.omtn.2022.03.022